Xencor (XNCR) Projected to Post Quarterly Earnings on Monday

Xencor (NASDAQ:XNCR) is expected to be releasing its Q2 2025 earnings data before the market opens on Monday, August 4th. Analysts expect Xencor to post earnings of ($0.78) per share and revenue of $22.59 million for the quarter.

Xencor (NASDAQ:XNCR) last issued its quarterly earnings results on Thursday, May 8th. The biopharmaceutical company reported ($0.66) earnings per share for the quarter, missing the consensus estimate of ($0.60) by ($0.06). Xencor had a negative return on equity of 31.94% and a negative net margin of 181.17%. The company had revenue of $32.73 million for the quarter, compared to analysts’ expectations of $23.44 million. During the same quarter last year, the company earned ($1.11) EPS. Xencor’s revenue for the quarter was up 104.6% compared to the same quarter last year. On average, analysts expect Xencor to post $-4 EPS for the current fiscal year and $-4 EPS for the next fiscal year.

Xencor Price Performance

Shares of NASDAQ XNCR opened at $9.24 on Monday. The stock’s 50-day moving average is $8.60 and its two-hundred day moving average is $11.70. The company has a debt-to-equity ratio of 0.16, a current ratio of 5.89 and a quick ratio of 5.89. Xencor has a 1-year low of $7.16 and a 1-year high of $27.24. The company has a market cap of $657.61 million, a price-to-earnings ratio of -3.02 and a beta of 0.85.

Analyst Ratings Changes

Several equities research analysts have weighed in on the company. Barclays cut their price target on Xencor from $22.00 to $6.00 and set an “underweight” rating on the stock in a report on Thursday, May 8th. Wedbush restated an “outperform” rating and set a $31.00 price target on shares of Xencor in a report on Wednesday, April 30th. Finally, William Blair assumed coverage on Xencor in a report on Monday, April 21st. They set an “outperform” rating on the stock. Two investment analysts have rated the stock with a sell rating and seven have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $28.00.

Insiders Place Their Bets

In other news, Director Kurt A. Gustafson sold 2,993 shares of the stock in a transaction dated Monday, June 16th. The stock was sold at an average price of $9.22, for a total value of $27,595.46. Following the transaction, the director owned 20,183 shares in the company, valued at approximately $186,087.26. This represents a 12.91% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, EVP Nancy Valente sold 4,616 shares of the stock in a transaction dated Friday, May 2nd. The shares were sold at an average price of $11.03, for a total value of $50,914.48. Following the completion of the transaction, the executive vice president owned 49,169 shares in the company, valued at approximately $542,334.07. The trade was a 8.58% decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 15,810 shares of company stock worth $154,123. Insiders own 5.23% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in the business. Goldman Sachs Group Inc. increased its holdings in shares of Xencor by 89.9% in the 1st quarter. Goldman Sachs Group Inc. now owns 726,734 shares of the biopharmaceutical company’s stock valued at $7,732,000 after acquiring an additional 344,088 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its stake in Xencor by 9.1% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 44,047 shares of the biopharmaceutical company’s stock worth $471,000 after buying an additional 3,692 shares during the last quarter. Finally, AQR Capital Management LLC purchased a new position in Xencor during the 1st quarter worth approximately $438,000.

About Xencor

Xencor, Inc, a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma.